KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)

Inclusion Criteria: * 1\. Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy * 2\. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: * 1\. History of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug * 2\. Pregnancy and/or breast feeding * 3\. Current participation in any interventional trial